-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA) Sees Large Decline in Short Interest
Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA) Sees Large Decline in Short Interest
Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA – Get Rating) was the target of a large drop in short interest during the month of December. As of December 30th, there was short interest totalling 174,600 shares, a drop of 11.6% from the December 15th total of 197,600 shares. Based on an average daily volume of 77,200 shares, the short-interest ratio is presently 2.3 days. Currently, 1.8% of the company's shares are short sold.
Comera Life Sciences Price Performance
CMRA stock traded down $0.07 during midday trading on Friday, hitting $1.40. The stock had a trading volume of 59,692 shares, compared to its average volume of 171,715. The business has a fifty day moving average price of $1.39 and a two-hundred day moving average price of $1.87. Comera Life Sciences has a 1-year low of $1.11 and a 1-year high of $11.44.
Get Comera Life Sciences alerts:Comera Life Sciences (NASDAQ:CMRA – Get Rating) last released its earnings results on Thursday, November 10th. The company reported ($0.20) EPS for the quarter. The company had revenue of $0.24 million during the quarter.
Insider Buying and Selling
In related news, major shareholder David Soane purchased 202,701 shares of the firm's stock in a transaction dated Wednesday, January 4th. The stock was bought at an average price of $1.23 per share, with a total value of $249,322.23. Following the completion of the purchase, the insider now owns 3,336,562 shares in the company, valued at approximately $4,103,971.26. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. 4.50% of the stock is owned by corporate insiders.Institutional Trading of Comera Life Sciences
Several hedge funds have recently modified their holdings of the stock. Bluefin Capital Management LLC bought a new stake in Comera Life Sciences in the second quarter valued at $73,000. Jane Street Group LLC acquired a new position in Comera Life Sciences during the 2nd quarter worth approximately $115,000. Arena Investors LP acquired a new stake in Comera Life Sciences in the third quarter valued at approximately $137,000. Virtu Financial LLC bought a new stake in shares of Comera Life Sciences during the third quarter valued at approximately $25,000. Finally, Lake Street Advisors Group LLC raised its position in shares of Comera Life Sciences by 216.5% during the third quarter. Lake Street Advisors Group LLC now owns 316,469 shares of the company's stock worth $510,000 after purchasing an additional 216,469 shares during the period. Institutional investors own 2.94% of the company's stock.
Comera Life Sciences Company Profile
(Get Rating)
Comera Life Sciences Holdings, Inc, a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions.
Read More
- Get a free copy of the StockNews.com research report on Comera Life Sciences (CMRA)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for Comera Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Comera Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA – Get Rating) was the target of a large drop in short interest during the month of December. As of December 30th, there was short interest totalling 174,600 shares, a drop of 11.6% from the December 15th total of 197,600 shares. Based on an average daily volume of 77,200 shares, the short-interest ratio is presently 2.3 days. Currently, 1.8% of the company's shares are short sold.
科美拉生命科學控股有限公司（NASDAQ：CMRA-獲得評級）是 12 月份短期利率大幅下降的目標。截至十二月三十日，總共有 174,600 股短息，較十二月十五日共 197,600 股股份下降 11.6%。根據每日平均成交量為 77,200 股，短息比率目前為 2.3 天。目前，該公司 1.8% 的股份賣空。
Comera Life Sciences Price Performance
科美拉生命科學價格性能
CMRA stock traded down $0.07 during midday trading on Friday, hitting $1.40. The stock had a trading volume of 59,692 shares, compared to its average volume of 171,715. The business has a fifty day moving average price of $1.39 and a two-hundred day moving average price of $1.87. Comera Life Sciences has a 1-year low of $1.11 and a 1-year high of $11.44.
CMRA 股票周五中午交易期間下跌 0.07 美元，觸及 1.40 美元。該股的交易量為 59,692 股，與其平均交易量為 171,715 股相比。該業務的五十天移動平均價格為 1.39 美元，兩百天移動平均價格為 1.87 美元。科美拉生命科學擁有 1 年低點 1.11 美元和 1 年高點 11.44 美元。
Comera Life Sciences (NASDAQ:CMRA – Get Rating) last released its earnings results on Thursday, November 10th. The company reported ($0.20) EPS for the quarter. The company had revenue of $0.24 million during the quarter.
科美拉生命科學（NASDAQ：CMRA-獲取評級）上次發布了其收益業績週四，11 月 10 日。該公司報告了本季度每股盈利（0.20 美元）。該公司在本季度的收入為 0.24 萬美元。
Insider Buying and Selling
內幕買賣
Institutional Trading of Comera Life Sciences
科美拉生命科學的機構交易
Several hedge funds have recently modified their holdings of the stock. Bluefin Capital Management LLC bought a new stake in Comera Life Sciences in the second quarter valued at $73,000. Jane Street Group LLC acquired a new position in Comera Life Sciences during the 2nd quarter worth approximately $115,000. Arena Investors LP acquired a new stake in Comera Life Sciences in the third quarter valued at approximately $137,000. Virtu Financial LLC bought a new stake in shares of Comera Life Sciences during the third quarter valued at approximately $25,000. Finally, Lake Street Advisors Group LLC raised its position in shares of Comera Life Sciences by 216.5% during the third quarter. Lake Street Advisors Group LLC now owns 316,469 shares of the company's stock worth $510,000 after purchasing an additional 216,469 shares during the period. Institutional investors own 2.94% of the company's stock.
幾個對沖基金最近修改了他們對股票的持有量。藍芬資本管理有限責任公司在第二季度購買了科美拉生命科學的新股份，價值為 73,000 美元。簡街集團有限責任公司在第二季度收購了科美拉生命科學的新職位，價值約為 115,000 美元。競技場投資 LP 在第三季度收購了科美拉生命科學的新股份，價值約為 137,000 美元。維圖金融有限責任公司在第三季度購買了科美拉生命科學股份的新股份，價值約為 25,000 美元。最後, 湖街顧問集團有限責任公司提出了其在科美拉生命科學股份的位置 216.5% 在第三季度.湖街顧問集團有限責任公司在此期間額外購買 216,469 股股票後，擁有該公司股票價值 510,000 美元的 316,469 股。機構投資者擁有公司股票的 2.94%。
Comera Life Sciences Company Profile
科美拉生命科學公司簡介
(Get Rating)
(取得評分)
Comera Life Sciences Holdings, Inc, a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions.
科美拉生命科學控股有限公司，是臨床前階段生命科學公司，開發了專有治療的內部產品組合，該產品結合了其專有配方平台 SQore。其 SQore 平台旨在實現靜脈注射（IV）生物製劑轉換為皮下（SQ）版本。
Read More
閱讀更多
- Get a free copy of the StockNews.com research report on Comera Life Sciences (CMRA)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- 獲取有關科美拉生命科學（CMRA）的研究報告
- 市場節拍週的回顧 — 1/16 — 1/20
- 老自治領是否顯示卡車正在擊中剎車？
- 諾德斯特龍將對減價的恐懼放入零售業
- 埃克森美孚股票：在買入點的醒目距離內
- 高股息收益的必和必拓認為中國推動 23 年增長
Receive News & Ratings for Comera Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Comera Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
接收科美拉生命科學日報的最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關科美拉生命科學及相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧